David Veitch will set up and lead Savient’s European organisation in order to introduce the company’s gout treatment Krystexxa (pegloticase) to this market.
Savient expects Krystexxa to be available in the EU on a named patient basis for treatment of chronic gout by the end of March.
Veitch has 24 years’ experience in the pharmaceutical industry, including 10 years at BMS, where he became Senior VP of European Marketing and Brand Commercialisation. He has also held managerial positions at SmithKline Beecham, now part of GlaxoSmithKline (GSK).
John Johnson, CEO and President of Savient, said of the company’s new executive: “David has spent more than twenty years in critical pharmaceutical leadership positions within the European markets and has a track record of successfully launching specialty products in Europe.”